RELYVRIO™ was generally well-tolerated in the CENTAUR trial1
ADVERSE REACTIONS REPORTED IN >5% OF RELYVRIO-TREATED PARTICIPANTS WITH ALS AND AT LEAST 5% GREATER THAN PLACEBO1*
ADVERSE REACTIONS REPORTED IN >5% OF RELYVRIO-TREATED PARTICIPANTS WITH ALS AND AT LEAST 5% GREATER THAN PLACEBO1*
Adverse Reaction
RELYVRIO
n=89
(%)
PLACEBO
n=48
(%)
Diarrhea†
25
19
Abdominal pain†
21
13
Nausea
18
13
Upper respiratory tract infection†
18
10
Fatigue†
12
6
Salivary hypersecretion
11
2
Dizziness
10
4
*Study 1 is the CENTAUR trial.
†Adverse reaction is composed of several similar terms.
- In the CENTAUR trial, 6% of participants taking RELYVRIO and 4% of participants taking placebo died during the 24-week study, which appeared to be related to ALS disease progression1
Incidence of Gastrointestinal (GI) Adverse Events by Study Week2,3
Incidence of Gastrointestinal (GI) Adverse Events by Study Week2,3
Originally randomized to placebo + SOC (n=48)
Originally randomized to RELYVRIO + SOC (n=89)
GI-related AEs occurred throughout the study, but were more frequent during the first 3 weeks of treatment.
GI-related AEs occurred throughout the study, but were more frequent during the first 3 weeks of treatment.
Originally randomized to placebo + SOC (n=48)
Originally randomized to RELYVRIO + SOC (n=89)
- The most common GI events reported in the RELYVRIO + SOC group were nausea, diarrhea, and abdominal pain1
- GI-related AEs occurred throughout the study and generally decreased to the same level as placebo for the rest of the trial4
Learn about the dosing of RELYVRIO
Stay Up-to-Date
Fill out the form below to stay informed and receive the latest information on RELYVRIO.
Thank you
We have sent a confirmation email and will share additional information about RELYVRIO as it becomes available.